HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tom Bäck Selected Research

Antibodies

1/2021Evaluation of therapeutic efficacy of 211At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer.
12/2017Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model.
3/2016Synthesis and Evaluation of Astatinated N-[2-(Maleimido)ethyl]-3-(trimethylstannyl)benzamide Immunoconjugates.
8/2014Sequential radioimmunotherapy with 177Lu- and 211At-labeled monoclonal antibody BR96 in a syngeneic rat colon carcinoma model.
8/2013Ex vivo activity quantification in micrometastases at the cellular scale using the α-camera technique.
9/2008Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Tom Bäck Research Topics

Disease

37Neoplasms (Cancer)
01/2024 - 05/2002
16Ovarian Neoplasms (Ovarian Cancer)
01/2021 - 11/2005
7Carcinoma (Carcinomatosis)
01/2017 - 10/2007
5Ascites
12/2017 - 11/2005
3Ovarian Epithelial Carcinoma
01/2023 - 01/2017
3Body Weight (Weight, Body)
12/2017 - 04/2013
3Residual Neoplasm
11/2015 - 11/2010
2Neoplasm Metastasis (Metastasis)
01/2022 - 08/2014
2Lymphoma (Lymphomas)
03/2015 - 11/2010
2Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
05/2013 - 07/2011
1Fatigue
01/2019
1Intestinal Perforation
01/2019
1Breast Neoplasms (Breast Cancer)
12/2017
1B-Cell Lymphoma (Lymphoma, B Cell)
03/2015
1Neoplasm Micrometastasis
08/2013
1Leukemia
05/2013
1Weight Loss (Weight Reduction)
04/2013
1Disease Progression
03/2013
1Myeloid Leukemia (Leukemia, Myelocytic)
07/2011

Drug/Important Bio-Agent (IBA)

13Monoclonal AntibodiesIBA
04/2023 - 03/2003
10Astatine-211IBA
04/2023 - 10/2007
6211At-labeled monoclonal antibody MX35IBA
01/2021 - 08/2006
6AntibodiesIBA
01/2021 - 09/2008
6Radioisotopes (Radionuclides)IBA
01/2018 - 11/2010
3Proteins (Proteins, Gene)FDA Link
12/2017 - 11/2010
3AstatineIBA
03/2016 - 12/2009
3Immunoconjugates (Immunoconjugate)IBA
03/2016 - 12/2005
3procaine isothiocyanate (PRIT)IBA
03/2013 - 11/2010
2Neoplasm Antigens (Tumor Antigens)IBA
04/2023 - 01/2015
2AntigensIBA
01/2019 - 01/2017
2Lysine (L-Lysine)FDA Link
12/2011 - 05/2002
1SolutionsIBA
01/2024
1Thorium Dioxide (Thorotrast)IBA
01/2023
1Contrast MediaIBA
01/2023
1Colloids (Colloid)IBA
01/2023
1RadiopharmaceuticalsIBA
10/2021
1farletuzumabIBA
01/2021
1Rituximab (Mabthera)FDA Link
01/2021
1Indicators and Reagents (Reagents)IBA
01/2019
1Membrane Transport Proteins (Biological Pump)IBA
01/2017
1TinIBA
03/2016
1EpitopesIBA
01/2015
1Lutetium-177IBA
08/2014
1HalogensIBA
08/2014
1Reducing AgentsIBA
08/2014
1BR96 monoclonal antibodyIBA
08/2014
1Eosine Yellowish-(YS) (Eosin)IBA
08/2013
1Hematoxylin (Haematoxylon)IBA
08/2013
1Lewis Y antigenIBA
04/2013
1AvidinIBA
12/2011
1BismuthIBA
07/2011
1StreptavidinIBA
11/2010
1Bismuth-213IBA
11/2010
1DOTA-biotin (90Y-DOTA-biotin)IBA
11/2010
1Biotin (Vitamin H)FDA Link
11/2010
1Dihydrotachysterol (AT 10)IBA
10/2010
1Trastuzumab (Herceptin)FDA Link
10/2007
1SuspensionsIBA
03/2003

Therapy/Procedure

19Radioimmunotherapy
04/2023 - 11/2005
18Therapeutics
04/2023 - 05/2002
6Aftercare (After-Treatment)
12/2017 - 11/2005
5Drug Therapy (Chemotherapy)
01/2023 - 07/2009
2Intravenous Injections
01/2021 - 01/2017
2Catheters
01/2019 - 07/2009
1Transcutaneous Electric Nerve Stimulation (TENS)
08/2013
1Hematopoietic Stem Cell Transplantation
05/2013
1Bone Marrow Transplantation (Transplantation, Bone Marrow)
05/2013
1Radiotherapy
10/2010